Alfia E. Pushkareva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Alfia E. Pushkareva has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Naufal Shamilevich Zagidullin
Federal State Budgetary Educational Institution of Higher Education “Bashkir State Medical University” of the Ministry of Healthcare of the Russian Federation
4 shared publications - V. Sh. Ishmetov
Bashkir State Medical University
3 shared publications - Diana F. Gareeva
Bashkir State Medical University
2 shared publications - M. R. Plotnikova
Bashkir State Medical University
2 shared publications - A. A. Dolganov
Bashkir State Medical University
1 shared publication - A. V. Pavlov
Bashkir State Medical University
1 shared publication
Latest Publications
- Open Access
- 20 September 2026
- Published by Moscow Regional Research and Clinical Institute (MONIKI) in Almanac of Clinical Medicine
- Vol. 54 (3) , 113-125
Ethnic variability of pharmacogenetic TPMT and NUDT15 variants in Russian populations: Implications for personalized thiopurine therapy
Background: Thiopurines, including azathioprine and 6-mercaptopurine, are widely used in the treatment of inflammatory and autoimmune diseases, as well as hematological malignancies; however, their use is limited by the risk of severe myelosuppression. Pharmacogenetic variants in the TPMT and NUDT15 genes significantly affect drug tolerability, and their frequencies vary markedly across ethnic groups, making population-based studies of these markers in different regions of Russia particularly important. Aim: To assess interethnic variability in the frequencies of clinically relevant TPMT rs1142345 and NUDT15 rs116855232 polymorphisms in populations of the Volga-Ural region, North Caucasus, and the Lower Volga region. Methods: Data from 1687 healthy males from 27 populations and 15 ethnogeographic groups (Bashkirs, Tatars, Mordvins, Chuvash, Mari, Udmurts, Komi, Besermyans, Kalmyks, Balkars, Karachays, Circassians, Ingush, Chechens, and Moldovans), collected during field expeditions in 2000–2025, were retrospectively analyzed. Information on date and place of birth, family history of disease, ethnicity of parents and grandparents (maternal and paternal lines), and causes of death of closed relatives was collected by questionnaire. Individuals with mixed ancestry were excluded. Genomic DNA was extracted from venous blood; genotyping of TPMT rs1142345 and NUDT15 rs116855232 was performed by real-time polymerase chain reaction with TaqMan probes. Results: The minor allele rs1142345*C of TPMT (TPMT*3C) was rare or absent in most of the studied groups, with the highest frequencies observed in Chuvash (3.65%), Circassians (3.23%), and Mordvins (3.16%). The minor allele rs116855232*T of NUDT15 (NUDT15*3) was more frequent in Kalmyks (15.6%), Bashkirs from Perm Krai (14.77%), and Bashkirs of the Samara and Saratov Regions (14.63%), whereas it was absent in Moldovans and occurred at minimal frequencies in Mordvins (0.52%), Chechens (1.03%) and Ingush (1.61%). The most significant differences in NUDT15*3 allele frequency were observed between Kalmyks and Mordvins (15.60% vs 0.52%; p = 2.7 × 10-9, p_FDR = 9.3 × 10-7), Kalmyks and Chechens (15.60% vs 1.03%; p = 2.4 × 10-8, p_FDR = 3.8 × 10-6), and Kalmyks and Moldovans (15.60% vs 0.0%; p = 3.2 × 10-8, p_FDR = 3.8 × 10-6). Among the Bashkir subgroups, the greatest differences were found between Bashkirs from Perm Krai and Mordvins (14.77% vs 0.52%; p = 1.4 × 10-6, p_FDR = 1.3 × 10-4), between Bashkirs from Samara and Saratov Regions and Mordvins (14.63% vs 0.52%; p = 2.5 × 10-6, p_FDR = 1.8 × 10-4), and between Bashkirs from Perm Krai and Moldovans (14.77% vs 0.0%; p = 3.4 × 10-6, p_FDR = 2.0 × 10-4) and Chechens (14.77% vs 1.03%; p = 8.0 × 10-6, p_FDR = 3.5 × 10-4). Conclusion: The results confirm substantial ethnic heterogeneity in the distribution of pharmacogenetic markers of thiopurine toxicity. The minor allele rs116855232*T of NUDT15 was significantly more prevalent in the studied populations than the minor allele rs1142345*C of TPMT, and its frequencies in several groups were comparable to those in East Asian populations. This supports the utility of genotyping for personalizing azathioprine therapy in Russian regions.
- 20 September 2026
- Published by Moscow Regional Research and Clinical Institute (MONIKI) in Almanac of Clinical Medicine
- Vol. 54 (3) , 113-125
Open AccessEthnic variability of pharmacogenetic TPMT and NUDT15 variants in Russian populations: Implications for personalized thiopurine therapy
Background: Thiopurines, including azathioprine and 6-mercaptopurine, are widely used in the treatment of inflammatory and autoimmune diseases, as well as hematological malignancies; however, their use is limited by the risk of severe myelosuppression. Pharmacogenetic variants in the TPMT and NUDT15 genes significantly affect drug tolerability, and their frequencies vary markedly across ethnic groups, making population-based studies of these markers in different regions of Russia particularly important. Aim: To assess interethnic variability in the frequencies of clinically relevant TPMT rs1142345 and NUDT15 rs116855232 polymorphisms in populations of the Volga-Ural region, North Caucasus, and the Lower Volga region. Methods: Data from 1687 healthy males from 27 populations and 15 ethnogeographic groups (Bashkirs, Tatars, Mordvins, Chuvash, Mari, Udmurts, Komi, Besermyans, Kalmyks, Balkars, Karachays, Circassians, Ingush, Chechens, and Moldovans), collected during field expeditions in 2000–2025, were retrospectively analyzed. Information on date and place of birth, family history of disease, ethnicity of parents and grandparents (maternal and paternal lines), and causes of death of closed relatives was collected by questionnaire. Individuals with mixed ancestry were excluded. Genomic DNA was extracted from venous blood; genotyping of TPMT rs1142345 and NUDT15 rs116855232 was performed by real-time polymerase chain reaction with TaqMan probes. Results: The minor allele rs1142345*C of TPMT (TPMT*3C) was rare or absent in most of the studied groups, with the highest frequencies observed in Chuvash (3.65%), Circassians (3.23%), and Mordvins (3.16%). The minor allele rs116855232*T of NUDT15 (NUDT15*3) was more frequent in Kalmyks (15.6%), Bashkirs from Perm Krai (14.77%), and Bashkirs of the Samara and Saratov Regions (14.63%), whereas it was absent in Moldovans and occurred at minimal frequencies in Mordvins (0.52%), Chechens (1.03%) and Ingush (1.61%). The most significant differences in NUDT15*3 allele frequency were observed between Kalmyks and Mordvins (15.60% vs 0.52%; p = 2.7 × 10-9, p_FDR = 9.3 × 10-7), Kalmyks and Chechens (15.60% vs 1.03%; p = 2.4 × 10-8, p_FDR = 3.8 × 10-6), and Kalmyks and Moldovans (15.60% vs 0.0%; p = 3.2 × 10-8, p_FDR = 3.8 × 10-6). Among the Bashkir subgroups, the greatest differences were found between Bashkirs from Perm Krai and Mordvins (14.77% vs 0.52%; p = 1.4 × 10-6, p_FDR = 1.3 × 10-4), between Bashkirs from Samara and Saratov Regions and Mordvins (14.63% vs 0.52%; p = 2.5 × 10-6, p_FDR = 1.8 × 10-4), and between Bashkirs from Perm Krai and Moldovans (14.77% vs 0.0%; p = 3.4 × 10-6, p_FDR = 2.0 × 10-4) and Chechens (14.77% vs 1.03%; p = 8.0 × 10-6, p_FDR = 3.5 × 10-4). Conclusion: The results confirm substantial ethnic heterogeneity in the distribution of pharmacogenetic markers of thiopurine toxicity. The minor allele rs116855232*T of NUDT15 was significantly more prevalent in the studied populations than the minor allele rs1142345*C of TPMT, and its frequencies in several groups were comparable to those in East Asian populations. This supports the utility of genotyping for personalizing azathioprine therapy in Russian regions.
- Open Access
- 18 March 2022
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 27 (1S) , 4872
Role of epicardial adipose tissue in the development of cardiovascular diseases
Epicardial adipose tissue (EAT) has unique properties due to its special anatomical structure, thermoregulation, and metabolic activity. Dysregulated EAT provokes the synthesis of pro-inflammatory cytokines, disorders in the metabolism of fats and glucose, as well as contributes to fatty degeneration of the myocardium and heart failure development. EAT may serve as a risk factor and biomarker for cardiovascular diseases, and is also a potential therapeutic target. The purpose of this review was to highlight current research data on EAT, secreted adipokines, their effect on target tissue metabolism, and to systematize the relationship between EAT and cardiovascular diseases. In particular, its function, role in heart failure, atrial fibrillation, as well as the prognostic value of various microRNAs determined in EAT are highlighted.
- 18 March 2022
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 27 (1S) , 4872
Open AccessRole of epicardial adipose tissue in the development of cardiovascular diseases
Epicardial adipose tissue (EAT) has unique properties due to its special anatomical structure, thermoregulation, and metabolic activity. Dysregulated EAT provokes the synthesis of pro-inflammatory cytokines, disorders in the metabolism of fats and glucose, as well as contributes to fatty degeneration of the myocardium and heart failure development. EAT may serve as a risk factor and biomarker for cardiovascular diseases, and is also a potential therapeutic target. The purpose of this review was to highlight current research data on EAT, secreted adipokines, their effect on target tissue metabolism, and to systematize the relationship between EAT and cardiovascular diseases. In particular, its function, role in heart failure, atrial fibrillation, as well as the prognostic value of various microRNAs determined in EAT are highlighted.
- Open Access
- 7 July 2021
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 26 (2S) , 4456
Serum biomarkers of cardiovascular complications in COVID-19
The coronavirus disease 2019 (COVID-19) affects not only the respiratory system, but also the cardiovascular system in 20-28% of cases, causing endothelial dysfunction, vasculitis, hyper- and hypocoagulation, myocarditis, endothelial dysfunction and other adverse effects. The presence of cardiovascular risk factors and diseases has been shown to worsen the disease severity and increase mortality from COVID-19. Recent studies have also found that elevations in some serum cardiovascular biomarkers can stratify the disease severity, in particular rates of hospitalizations to an internal medicine or intensive care unit, intubation, and mortality. They can be divided into markers of damage (TnT/I, creatine phosphokinase (CPK) and CPK-MB, myoglobin, NT-proBNP), coagulation (prothrombin time, fibrinogen and D-dimer), as well as prospective biomarkers for which the available evidence base is limited but there is a pathophysiological rationale (homocysteine and sST2). This review presents studies on the use of above serum biomarkers to stratify the risk of death in patients with COVID-19.
- 7 July 2021
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 26 (2S) , 4456
Open AccessSerum biomarkers of cardiovascular complications in COVID-19
The coronavirus disease 2019 (COVID-19) affects not only the respiratory system, but also the cardiovascular system in 20-28% of cases, causing endothelial dysfunction, vasculitis, hyper- and hypocoagulation, myocarditis, endothelial dysfunction and other adverse effects. The presence of cardiovascular risk factors and diseases has been shown to worsen the disease severity and increase mortality from COVID-19. Recent studies have also found that elevations in some serum cardiovascular biomarkers can stratify the disease severity, in particular rates of hospitalizations to an internal medicine or intensive care unit, intubation, and mortality. They can be divided into markers of damage (TnT/I, creatine phosphokinase (CPK) and CPK-MB, myoglobin, NT-proBNP), coagulation (prothrombin time, fibrinogen and D-dimer), as well as prospective biomarkers for which the available evidence base is limited but there is a pathophysiological rationale (homocysteine and sST2). This review presents studies on the use of above serum biomarkers to stratify the risk of death in patients with COVID-19.
- 30 June 2021
- Published by Springer Nature in Molecular Biology Reports
- Vol. 48 (6) , 5355-5362
Genetic predictors of sick sinus syndrome
Sick sinus syndrome (SSS) encompasses a group of conduction disorders characterized by the inability of sinoatrial node to perform its pacemaker function. Our aim was to identify genetic predictors of SSS in a prospective cohort of patients admitted to the clinic for pacemaker implantation using single-locus and multilocus approaches. We performed genotyping for polymorphic markers of CLCNKA (rs10927887), SCN10A (rs6795970), FNDC3B (rs9647379), MIR146A (rs2910164), SYT10 (rs7980799), MYH6 (rs365990), and KCNE1 (rs1805127) genes in the group of 284 patients with SSS and 243 healthy individuals. Associations between the studied loci and SSS were tested using logistic regression under recessive genetic model using sex and age as covariates. Multilocus analysis was performed using Markov chain Monte Carlo method implemented in the APSampler program. Correction for multiple testing was performed using Benjamini–Hochberg procedure. We detected an individual association between KCNE1 rs1805127*A allele and SSS in the total study group (OR 0.43, PFDR = 0.028) and in the subgroup of patients with 2nd or 3rd degree sinoatrial block (OR 0.17, PFDR = 0.033), and identified seven allelic patterns associated with the disease. SCN10A rs6795970*T and MIR146A rs2910164*C alleles were present in all seven combinations associated with SSS. The highest risk of SSS was conferred by the combination SCN10A rs6795970*T+FNDC3B rs9647379*C+MIR146A rs2910164*C+SYT10 rs7980799*C+KCNE1 rs1805127*G (OR 2.98, CI 1.77–5.00, P = 1.27 × 10–5, PFDR = 0.022). Our findings suggest that KCNE1 rs1805127 polymorphism may play a role in susceptibility to sinoatrial node dysfunction, particularly presenting as 2nd or 3rd degree sinoatrial block, and the risk-modifying effect of other studied loci is better detected using multilocus approach.
- 30 June 2021
- Published by Springer Nature in Molecular Biology Reports
- Vol. 48 (6) , 5355-5362
Genetic predictors of sick sinus syndrome
Sick sinus syndrome (SSS) encompasses a group of conduction disorders characterized by the inability of sinoatrial node to perform its pacemaker function. Our aim was to identify genetic predictors of SSS in a prospective cohort of patients admitted to the clinic for pacemaker implantation using single-locus and multilocus approaches. We performed genotyping for polymorphic markers of CLCNKA (rs10927887), SCN10A (rs6795970), FNDC3B (rs9647379), MIR146A (rs2910164), SYT10 (rs7980799), MYH6 (rs365990), and KCNE1 (rs1805127) genes in the group of 284 patients with SSS and 243 healthy individuals. Associations between the studied loci and SSS were tested using logistic regression under recessive genetic model using sex and age as covariates. Multilocus analysis was performed using Markov chain Monte Carlo method implemented in the APSampler program. Correction for multiple testing was performed using Benjamini–Hochberg procedure. We detected an individual association between KCNE1 rs1805127*A allele and SSS in the total study group (OR 0.43, PFDR = 0.028) and in the subgroup of patients with 2nd or 3rd degree sinoatrial block (OR 0.17, PFDR = 0.033), and identified seven allelic patterns associated with the disease. SCN10A rs6795970*T and MIR146A rs2910164*C alleles were present in all seven combinations associated with SSS. The highest risk of SSS was conferred by the combination SCN10A rs6795970*T+FNDC3B rs9647379*C+MIR146A rs2910164*C+SYT10 rs7980799*C+KCNE1 rs1805127*G (OR 2.98, CI 1.77–5.00, P = 1.27 × 10–5, PFDR = 0.022). Our findings suggest that KCNE1 rs1805127 polymorphism may play a role in susceptibility to sinoatrial node dysfunction, particularly presenting as 2nd or 3rd degree sinoatrial block, and the risk-modifying effect of other studied loci is better detected using multilocus approach.
- Open Access
- 25 June 2020
- Published by Arterialnaya Gipertenziya in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
- Vol. 26 (3) , 240-247
Renin-angiotensin-aldosterone system in new coronavirus infection 2019
Ренин-ангиотензиновая система при новой коронавирусной инфекции COVID-2019
- 25 June 2020
- Published by Arterialnaya Gipertenziya in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
- Vol. 26 (3) , 240-247
Open AccessRenin-angiotensin-aldosterone system in new coronavirus infection 2019
Ренин-ангиотензиновая система при новой коронавирусной инфекции COVID-2019